Off-label-dosing of non-vitamin K-dependent oral antagonists in AF patients before and after stroke: results of the prospective multicenter Berlin Atrial Fibrillation Registry.
Atrial fibrillation
Ischemic stroke
NOAC
Under-dosing
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
19
07
2021
accepted:
18
10
2021
revised:
17
10
2021
pubmed:
1
11
2021
medline:
11
1
2022
entrez:
31
10
2021
Statut:
ppublish
Résumé
We aimed to analyze prevalence and predictors of NOAC off-label under-dosing in AF patients before and after the index stroke. The post hoc analysis included 1080 patients of the investigator-initiated, multicenter prospective Berlin Atrial Fibrillation Registry, designed to analyze medical stroke prevention in AF patients after acute ischemic stroke. At stroke onset, an off-label daily dose was prescribed in 61 (25.5%) of 239 NOAC patients with known AF and CHA At stroke onset, off-label dosing was present in one out of four, and under-dosing in one out of five NOAC patients. Under-dosing of rivaroxaban or apixaban was related to old age. In-hospital treatment after stroke reduced off-label NOAC dosing, but one out of ten NOAC patients was under-dosed at discharge. NCT02306824.
Identifiants
pubmed: 34718884
doi: 10.1007/s00415-021-10866-2
pii: 10.1007/s00415-021-10866-2
pmc: PMC8739306
doi:
Substances chimiques
Anticoagulants
0
Banques de données
ClinicalTrials.gov
['NCT02306824']
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
470-480Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151
doi: 10.1056/NEJMoa0905561
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891
doi: 10.1056/NEJMoa1009638
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992
doi: 10.1056/NEJMoa1107039
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104
doi: 10.1056/NEJMoa1310907
Xian Y, Xu H, O’Brien EC, Shah S, Thomas L, Pencina MJ, Fonarow GC, Olson DM, Schwamm LH, Bhatt DL et al (2019) Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study. JAMA Neurol 76(10):1192–1202
doi: 10.1001/jamaneurol.2019.2099
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE et al (2020) ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL et al (2019) 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation 140(2):e125–e151
doi: 10.1161/CIR.0000000000000665
(AWMF) AdWMF: S3-Leitlinie Sekundärprophylaxe ischämischer Schlaganfall und transitorische ischämische Attacke
Haeusler KG, Tütüncü S, Kunze C, Schurig J, Malsch C, Harder J, Wiedmann S, Dimitrijeski B, Ebinger M, Hagemann G et al (2019) Oral anticoagulation in patients with atrial fibrillation and acute ischaemic stroke: design and baseline data of the prospective multicentre Berlin Atrial Fibrillation Registry. Europace 21(11):1621–1632
doi: 10.1093/europace/euz199
Tanislav C, Allendörfer J, Pfeilschifter W, Fuest S, Stein M, Meyer M, Reuter I, Kaps M, Misselwitz B (2018) One decade of oral anticoagulation in stroke patients: results from a large country-wide hospital-based registry. Int J Stroke 13(3):308–312
doi: 10.1177/1747493017733928
Hohnloser SH, Basic E, Nabauer M (2019) Uptake in antithrombotic treatment and its association with stroke incidence in atrial fibrillation: insights from a large German claims database. Clin Res Cardiol 108(9):1042–1052
doi: 10.1007/s00392-019-01437-7
Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, Ezekowitz MD, Fonarow GC, Gersh BJ, Goldhaber S et al (2017) International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J 194:132–140
doi: 10.1016/j.ahj.2017.08.011
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V et al (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39(16):1330–1393
doi: 10.1093/eurheartj/ehy136
Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J et al (2016) Off-label dosing of non-vitamin k antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry. J Am Coll Cardiol 68(24):2597–2604
doi: 10.1016/j.jacc.2016.09.966
Steinberg BA, Washam JB (2017) Appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. Trends Cardiovasc Med 27(8):567–572
doi: 10.1016/j.tcm.2017.06.012
Miyazaki M, Matsuo K, Uchiyama M, Nakamura Y, Sakamoto Y, Misaki M, Tokura K, Jimi S, Okamura K, Adachi S et al (2020) Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study. J Pharm Health Care Sci 6:2
doi: 10.1186/s40780-020-0157-z
Ablefoni K, Buchholz A, Ueberham L, Hilbert S, Dagres N, Husser D, Hindricks G, Bollmann A (2019) Initial rivaroxaban dosing in patients with atrial fibrillation. Clin Cardiol 42(10):873–880
doi: 10.1002/clc.23235
Wang KL, Lopes RD, Patel MR, Büller HR, Tan DS, Chiang CE, Giugliano RP (2019) Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Eur Heart J 40(19):1492–1500
doi: 10.1093/eurheartj/ehy802
Steinberg BA, Shrader P, Pieper K, Thomas L, Allen LA, Ansell J, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV et al (2018) Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). J Am Heart Assoc 7(4)
Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG, Camm AJ (2019) Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. Eur Heart J Cardiovasc Pharmacother 5(2):70–79
doi: 10.1093/ehjcvp/pvy041
Hatano S (1976) Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 54(5):541–553
pubmed: 1088404
pmcid: 2366492
Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V et al (1989) Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20(7):864–870
doi: 10.1161/01.STR.20.7.864
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19(5):604–607
doi: 10.1161/01.STR.19.5.604
Ingelheim B (2019) Fachinformation Pradaxa 150 mg Hartkapseln
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955–962
doi: 10.1016/S0140-6736(13)62343-0
Haas S (2015) im Namen des G-AFSC: [GARFIELD-AF - First data on healthcare of patients with atrial fibrillation in Germany]. Dtsch Med Wochenschr 140(Suppl 1):S13-14
pubmed: 26069039
Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma C, Zint K, Elsaesser A et al (2015) Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF Registry Phase II. Am J Med 128(12):1306-1313.e1301
doi: 10.1016/j.amjmed.2015.07.013
Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, Matsumoto M, Kojima T, Hanada S, Nomoto K et al (2017) Current use of direct oral anticoagulants for atrial fibrillation in Japan: findings from the SAKURA AF Registry. J Arrhythm 33(4):289–296
doi: 10.1016/j.joa.2016.11.003
Paikin JS, Haroun MJ, Eikelboom JW (2011) Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. Expert Rev Cardiovasc Ther 9(3):279–286
doi: 10.1586/erc.11.21
Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T, Dan GA, Kalarus Z, Tavazzi L et al (2019) Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. Europace 21(7):1013–1022
doi: 10.1093/europace/euz032
Haas K, Purrucker JC, Rizos T, Heuschmann PU, Veltkamp R (2019) Rationale and design of the Registry of Acute Stroke Under Novel Oral Anticoagulants-prime (RASUNOA-prime). Eur Stroke J 4(2):181–188
doi: 10.1177/2396987318812644
Stoll S, Macha K, Marsch A, Gerner ST, Siedler G, Fröhlich K, Volbers B, Strasser EF, Schwab S, Kallmünzer B (2020) Ischemic stroke and dose adjustment of oral factor Xa inhibitors in patients with atrial fibrillation. J Neurol 267(7):2007–2012
doi: 10.1007/s00415-020-09795-3
Hellwig S, Grittner U, Audebert H, Endres M, Haeusler KG (2018) Non-vitamin K-dependent oral anticoagulants have a positive impact on ischaemic stroke severity in patients with atrial fibrillation. EP Europace 20(4):569–574
doi: 10.1093/europace/eux087